FlowCardia appoints Barys as COO
This article was originally published in Clinica
Executive Summary
Chris Barys has joined FlowCardia, a developer of endovascular devices for treating chronic total occlusions (CTOs), as chief operating officer. Mr Barys joins the Sunnyvale, California company from Edwards Lifesciences, where he served as vice-president of sales and marketing for the peripheral vascular systems business. In his new role at FlowCardia, he will oversee R&D, quality, clinical and regulatory functions as well as sales and marketing. The company said adoption of its Crosser catheter, designed to recanalise CTOs in the central lumen of the artery, is picking up pace and there is a significant increase in sales activity. Commercialisation of the product began in February 2008
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.